RetaCalc
Protocol library
SingleApproved OtherMixedModerate confidenceSourced

Gonadorelin

Synthetic GnRH with specialist diagnostic and pulsatile fertility evidence. Clinical schedules rely on pumps, endocrine monitoring and indication-specific adjustment.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Vial-aware arithmetic

No reconstitution example shown

The cited human regimen uses a specialist infusion pump with weight- and response-adjusted pulses; a manual U-100 syringe example would not reproduce that delivery system or monitoring.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human StudySubcutaneous or intravenous infusion pumpOne pulse every 120 minutes
People with hypogonadotropic infertility in specialist care

Pulsatile subcutaneous or intravenous GnRH studied at 5 micrograms per pulse every 120 minutes with monitored adjustment

The review describes pump-based fertility treatment and response-guided changes, not manual intermittent injections.

View source
Evidence GapPulsatile subcutaneous via pump in mechanistic mentionsRoughly every 2 to 4 hours in mechanistic mentions
authenticated research-forum (Peppys) discussion

No reproducible community dose, reconstitution recipe or schedule is posted; gonadorelin appears only as a mechanistic mention that GnRH agents need impractical pulsatile dosing roughly every two to four hours, often via a pump, because continuous stimulation down-regulates receptors

Forum provenance from an authenticated archive with usernames omitted. The archive treats pulsatile GnRH delivery as impractical and generally prefers hCG/hMG or ultimately TRT; the only gonadorelin-specific item beyond mechanism is a grey-market catalogue line for 2 mg vials, which is availability, not a dose. This preserves the evidence gap rather than manufacturing a schedule.

View source

Evidence summary

Synthetic GnRH with specialist diagnostic and pulsatile fertility evidence. Clinical schedules rely on pumps, endocrine monitoring and indication-specific adjustment.

Protocol basis

The evidence supports diagnostic boluses and pump-generated pulses in narrowly defined endocrine settings. A vial calculator cannot reproduce the monitoring or delivery system.

What remains uncertain

Current product availability and authorised indications vary by jurisdiction; retail research vials are not automatically equivalent to labelled medicines.

Online research community archive check

No gonadorelin occurrence was found in the reviewed raw online research community archive. The specialist pump schedule above comes from the cited clinical literature, not a community protocol.

Community provenance (Peppys)

An authenticated research-forum archive contains no reproducible gonadorelin dose, reconstitution recipe or schedule. Gonadorelin surfaces only as a mechanistic mention: forum discussion describes GnRH agents as requiring impractical pulsatile dosing roughly every two to four hours, often via a pump, because continuous stimulation down-regulates receptors, and generally favours hCG/hMG or ultimately TRT. The only gonadorelin-specific item beyond mechanism is a grey-market catalogue line for 2 mg vials, which indicates availability rather than a protocol. Usernames are omitted and the evidence gap is preserved rather than filled with a schedule.

Warnings and contraindications

Pulsatile gonadorelin therapy requires specialist fertility or endocrine supervision.
Bolus diagnostic use and pump-based fertility treatment are different protocols.
Ovarian response, pregnancy risk and pituitary function require clinical monitoring.